Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells $3,524,080.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the transaction, the insider directly owned 107,193 shares of the company’s stock, valued at $13,491,310.98. The trade was a 20.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Johanna Mercier also recently made the following trade(s):

• On Wednesday, October 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $118.08, for a total transaction of $354,240.00.
• On Monday, September 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00.

Gilead Sciences Stock Performance

Shares of GILD opened at $124.99 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a market capitalization of $155.07 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 0.81 and a beta of 0.32. The company’s 50 day simple moving average is $118.23 and its 200 day simple moving average is $113.37. Gilead Sciences, Inc. has a 1 year low of $88.07 and a 1 year high of $128.70.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the previous year, the company earned $2.02 EPS. Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is 48.99%.

Wall Street Analyst Weigh In

Several analysts have commented on GILD shares. Scotiabank assumed coverage on Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price target for the company. BMO Capital Markets raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a report on Friday, October 31st. Daiwa Capital Markets upped their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Finally, TD Cowen increased their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $130.45.

Institutional Investors Weigh In On Gilead Sciences

Several large investors have recently made changes to their positions in the business. Brighton Jones LLC boosted its position in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $215,000. Diversify Advisory Services LLC boosted its position in shares of Gilead Sciences by 44.1% in the first quarter. Diversify Advisory Services LLC now owns 3,622 shares of the biopharmaceutical company’s stock worth $377,000 after buying an additional 1,109 shares during the period. Private Advisor Group LLC grew its stake in shares of Gilead Sciences by 10.4% in the first quarter. Private Advisor Group LLC now owns 38,275 shares of the biopharmaceutical company’s stock valued at $4,289,000 after buying an additional 3,593 shares in the last quarter. Finally, Kestra Private Wealth Services LLC raised its holdings in shares of Gilead Sciences by 0.8% during the 1st quarter. Kestra Private Wealth Services LLC now owns 29,596 shares of the biopharmaceutical company’s stock valued at $3,316,000 after buying an additional 228 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.